ApprovalTrail

Approval · Notice of Compliance 38384 · 2026

CAPVAXIVE: Notice of Compliance 38384

Issued September 29, 2026

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
38384
Date
September 29, 2026
Company
Merck Canada IncKirkland, Quebec, Canada
Product type
Biologic
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
New indication: CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes (3, 6A, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) in: • children and adolescents 2 to less than 18 years of age who are at increased risk for pneumococcal disease and who have previously completed a primary pneumococcal vaccination regimen.

Products in this notice

BrandDINStatus today
CAPVAXIVENot yet assigned—

Medicinal ingredients